Slide 1: Annual Meeting of Shareholders
Annual Meeting of Shareholders May 26, 2020
Slide 2: Forward-looking statement
Forward-looking statement This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current bel
Slide 3: Annual Meeting of Shareholders
Annual Meeting of Shareholders May 26, 2020
Slide 4: Board of Directors
Board of Directors Leslie A. Brun Thomas R. Cech, Mary Ellen Coe Pamela J. Craig Kenneth C. Frazier Ph.D. Thomas H. Glocer Risa J. Lavizzo- Paul B. Rothman, Patricia F. Russo Christine E. Seidman, Mourey, M.D. M.D. M.D. Inge G. Thulin Kathy J. Warden Peter C. Wendell
Slide 5: Retiring Board Members
Retiring Board Members Rochelle B. Lazarus Wendell P. Weeks
Slide 6: Executive Committee
Executive Committee Kenneth C. Frazier Sanat Chattopadhyay Frank Clyburn Robert M. Davis Richard R. DeLuca Jr. Julie L. Gerberding, Steven C. Mizell Michael T. Nally Roger M. Perlmutter, Jennifer Zachary M.D., M.P.H. M.D., Ph.D.
Slide 7: Merck
€ MERCK
Slide 8: 8
8
Slide 9: COVID-19 response
COVID-19 response & MERCK
Slide 10: COVID-19 response
COVID-19 response & MERCK
Slide 11: 11
11
Slide 12: Thank You
THANK YOU C
Slide 13: COVID-19 response
COVID-19 response
Slide 14: COVID-19 response
COVID-19 response
Slide 15: Full Year 2019 Highlights
Full Year 2019 Highlights Pharmaceutical sales Animal Health sales Merck FY 2019 WORLDWIDE SALES $41.8B $4.4B 11% growth 4% growth $46.8B 14% ex-exchange 9% ex-exchange Key drivers Key drivers STRONG GROWTH FROM DRIVEN BY ANTELLIQ PRODUCTS 11% growth LYNPARZA, KEYTRUDA, LENVIMA, AND SALES OF BRAVECT
Slide 16: 1Q 2020 Highlights
1Q 2020 Highlights Pharmaceutical sales Animal Health sales Merck Q1 2020 WORLDWIDE SALES $10.7B $1.2B 10% growth 18% growth $12.1B 12% ex-exchange 21% ex-exchange Key drivers Key drivers STRONG GROWTH FROM DRIVEN BY ANIMAL HEALTH 11% growth KEYTRUDA, GARDASIL/GARDASIL 9, INTELLIGENCE AND BRAVECTO 1
Slide 17: 1Q 2020 Oncology: KEYTRUDA +46% YOY
1Q 2020 Oncology KEYTRUDA Performance1 +46% YOY 1. All growth rates exclude the impact of foreign exchange.
Slide 18: 1Q 2020 Vaccines: GARDASIL +33% YOY
1Q 2020 Vaccines GARDASIL Performance1 +33% YOY 1. All growth rates exclude the impact of foreign exchange.
Slide 19: 1Q 2020 Hospital: BRIDION +19% YOY
1Q 2020 Hospital BRIDION Performance1 +19% YOY 1. All growth rates exclude the impact of foreign exchange.
Slide 20: 1Q 2020 Animal Health +21% YOY
1Q 2020 Animal Health Overall Performance1 +21% YOY 1. All growth rates exclude the impact of foreign exchange.
Slide 21: Organon
“i= ORGANON
Slide 22: To all our frontliners: thank you for your sacrifice every day
TOALL OUR FRONTLINERS : THANK, Yon For YOUR SACRIFICE EVERY bAY J J
Slide 23: Research and development highlights
Research and development highlights Annual Meeting of Shareholders May 26, 2020 Roger M. Perlmutter
Slide 24: Vaccination with Investigational Ebola Vaccine, V920
Vaccination with Investigational Ebola (Zaire) Vaccine, V920 (Merck) Democratic Republic of Congo July 2019
Slide 25: SARS-CoV-2, a novel coronavirus
SARS-CoV-2, a novel coronavirus
Slide 26: Portrait of SARS-CoV-2: the virus responsible for the COVID-19 pandemic
Portrait of SARS-CoV-2: the virus responsible for the COVID-19 pandemic 90° Viral membrane Adapted from Wrapp et al (2020) Science 367: 1260-1263
Slide 27: Four important partnerships will help Merck address COVID-19
Four important partnerships will help Merck to address the challenge posed by COVID-19 • Supporting the Institute for Systems Biology in characterizing the human immune response to COVID-19 at the molecular and cellular level • Partnered with the International AIDS Vaccine Initiative (IAVI) to devel
Slide 28: Our oncology franchise continues to gain strength
Our oncology franchise continues to gain strength … Leading immuno-oncology therapy in the world Leading PARP inhibitor around the world Potent multi-kinase inhibitor advantaged in combination with KEYTRUDA
Slide 29: Two new investigational drug candidates added through business development
… and we have added two important new investigational drug candidates through business development
Slide 30: Von-Hippel Lindau Disease: a target for MK-6482
Von-Hippel Lindau Disease: a target for MK-6482 A multi-system disease with most patients having several different tumors Advanced/ Benign Tumors Malignant Tumors • CNS Hemangioblastoma • RCC (25-60%) (70-80%) • Pheochromocytoma • Retinal Hemangioblastoma (10-20%) (50-60%) • Pancreatic NET • Pancrea
Slide 31: Beyond oncology, our late-stage pipeline is quite broad
Beyond oncology, our late-stage pipeline is quite broad Novel Vaccines: invasive pneumococcal disease (V114), dengue fever (V181), cytomegalovirus (V160) Cardiovascular: vericiguat for worsening heart failure Neuroscience: gefapixant for chronic cough Antimicrobials: RECARBRIO™, ZERBAXA™ HIV/AIDS: P
Slide 32: Merck
€ MERCK
Slide 33: Board of Directors
Board of Directors Leslie A. Brun Thomas R. Cech, Mary Ellen Coe Pamela J. Craig Kenneth C. Frazier Ph.D. Thomas H. Glocer Risa J. Lavizzo- Paul B. Rothman, Patricia F. Russo Christine E. Seidman, Mourey, M.D. M.D. M.D. Inge G. Thulin Kathy J. Warden Peter C. Wendell
Slide 34: Merck
€ MERCK